Notice of correction  by unknown
Notice of correction 
In the November 1998 issue of the Journal, in the article by Alderman and associates titled "Analysis 
of Coronary Graft Patency After Aprotinin Use: Results From the International Multicenter Aprotinin 
Graft Patency Experience (IMAGE) Trial" (1998; 116:716-30), an error was made. In Table I, the 
heading "Angiography performed" should extend over three subheadings: "All sites," US sites," and 
"Danish and Israeli sites." The corrected table is given below. 
Table I. Characteristics of all patients and those included in the assessment oj'the saphenous vein grafts 
Patient No. 
Preop ASAINSAID (%) 
Clinical featnres 
Age (yr, mean ± SD) 
Male (%) 
Weight (kg, mean ± SD) 
BSA (m. mean ± SD) 
NYHA class III-IV (%) 
MI S 30 d prcop (%) 
LVEF S 0.5 (%) 
Adjunctive drugs 
ASA within 2 days of operation 
(%) 
Total protamine (mg, 
mean ± SD) 
Total heparin (U, 
mean± SD) 
Laboratory analyses 
Preop PTT (s, mean ± SD) 
Preop Hgb (g1dL, mean ± SD) 
Preop creatinine (mgfdL 
mean ± SD) 
Graft insertions (by patient) 
Total/patient (mean ± SD) 
SVGfpatient (mean ± SD) 
Y or sequential SVG (%) 
ITA graft (%) 
Total graft insertions (No.) 
Distal vessel S 1.5 111m 
(o/c of grafts) 
Distal vessel quality: 
Good (% of grafts) 
Fairfpoor (% of grafts) 
Graft size: 
Large (% of grafts) 
f'<omlalfsmall (% of grafts) 




61.8 ± 9.1 
87.4 
81.7 ± 14.1 






59,200 ± 17,537 
31.6± 14.3 
13.98 ± 1.2 
1.13 ± 0.23 
3.03 ± 0.81 












62.3 ± 9.1 
86.9 
83.3 ± 15.0 





337 ± 10.5 
59,627 ± 15,571 
32.4 ± 16.6 
13.97 ± 1.3 
1.3 ± 0.21 
3.03 ± 0,85 














64,3 ± 9.7t 
85.1 
82.3 ± 14.9 






59,567 ± 20.196 
34,0 ± 22,0 
13.72± 1.4"[ 
1.15 ± 0.24 















61.8 ± 9.0t 
88.3 
82.5 ± 14.4 





341 ± 109'!' 
59,410 ± 16,002 
3L7 ± 14.0 
14.03 ± Ut 
1.13 ± 0.22 
3.08 ± 0,79 












61.6 ± 9.4 
90.6 
85.9 ± 15.0 





369 ± 105 
56,560 ± 14,517 
36.1 ± 16.2 
14.04± 1.4 
1.11 ± 0.24 
3.08 ± 0,74 













62.0 ± 8.6 
85.7 
78.5 ± 12.5::: 





309 ± 104+ 
62,7R2 ± 17,015:1: 
26.4 ± 8,2 
14.01 ± 1.3 
1.15±0,19 
3.07 ± 0,84 









sve, Saphenous vein graft; NSAJD, non:-.ternidai anti-inflammatory drug: ASA, aCdyl'ialic)'lic acid (a:-.pirin): HSA, body surface area: I.Vf~f; left ventricular ejection 
fraction; PIT, partial thromboplastin time; Hgb. hemoglobin. 
"'Thirty patlenls underwent angiography. but had no vein grafts. 
tP < .01 when comparing angiography and no-angiography groups. 
tP < .01 when comparing US and European ~ites. 
635 
